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The aim of this study was to examine the effects of oral and transdermal oestrogen replacement therapy on the risk of colorectal
cancer. Data from a nested case–control study, designed to investigate the effect of hormone replacement therapy (HRT) on
colorectal cancer were analysed. New cases of colorectal cancer, diagnosed between 1992 and mid-1998 (N¼1197), were
identified using the Saskatchewan Cancer Agency cancer registry. Women X50 years of age, eligible for coverage by the
Saskatchewan Prescription Drug Plan, were included in the study. Four controls per case were age matched to cases, using incidence
density sampling. The outpatient prescription drug plan database was used to ascertain oestrogen prescriptions. Women were
classified according to history of transdermal (TDE) and oral (OE) oestrogen use. Conditional logistic regression was used to estimate
odds ratios (ORs) and 95% confidence intervals (CIs). Compared with women who had never used HRT, ORs for o3 and X3 years
of TDE use and colorectal cancer were 0.69 (95% CI: 0.43–1.10) and 0.33 (95% CI: 0.12–0.95), and for OE use were 0.90 (95% CI:
0.73–1.01) and 0.75 (95% CI: 0.60–0.93), respectively. The risk reduction for colorectal cancer with TDE may be greater in
magnitude than that which has been reported for oral HRT.
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The release of results from the Women’s Health Initiative (WHI)
(Writing Group for the Women’s Health Initiative Investigators,
2002) and the Heart and Oestrogen/Progestin Replacement Study
(HERS II) (Grady et al, 2002; Hulley et al, 2002) trials in July 2002
clarified some of the risks and benefits of hormone replacement
therapy (HRT) that have been debated for decades. Currently, most
experts appear to agree that only women experiencing menopausal
symptoms should be prescribed oral combined oestrogen–progesta-
gen therapy (Blake et al, 2002), since among older postmenopausal
women the evidence suggests that the risk of overall harm outweighs
the potential for benefit. Experts also agree that systemic hormone
therapy is the most effective treatment for vasomotor and other
menopausal symptoms (Greendale et al, 1998; Blake et al, 2002).
Hence, for 10–25% of postmenopausal women who experience
d i s t r e s s i n gm e n o p a u s a ls y m p t o m s ,H R Tw i l lc o n t i n u et ob eat h e r a p y
of choice (Yusuf and Anand, 2002).
The results from the WHI (Writing Group for the Women’s Health
Initiative Investigators, 2002) randomised controlled trial and
numerous observational studies are consistent in their findings that
suggest that HRT is protective against colorectal cancer (Furner et al,
1989; Jacobs et al, 1994; Folsom et al, 1995; Newcomb and Storer,
1995; Persson et al,1 9 9 6 ;K a m p m a net al, 1997; Fernandez et al, 1998;
Grodstein et al, 1998; Prihartono et al, 2000). All of these studies,
however, have focused exclusively on the use of oral oestrogen (OE).
This may be due in part to the higher prevalence of OE use among
women, compared with transdermal oestrogen (TDE). However, since
the availability of TDE in the mid-1980s, its use has been increasing in
both Canada and the US (Wysowski et al, 1995).
While evidence from clinical studies demonstrate important
metabolic and biologic differences between oral and transdermal
HRT (Chetkowski et al, 1986; IARC Working Group on Hormonal
Contraception and Post-menopausal Hormonal Therapy, 1999;
Gruber and Huber, 2001; Campagnoli et al, 2002), limited information
is available relating the mode of hormone delivery (oral vs
transdermal) to clinically important outcomes. Faced with the
decision to begin HRT or not, women need to weigh the health
risks against the benefits of menopausal symptom control. Provided
that there is sufficient knowledge about the health effects of various
HRT formulations and modes of delivery, women and their
physicians could potentially individualise treatment with HRT to
minimise the health risks and optimise benefit.
In this population-based case–control study, we examine the
effects of transdermal and OE administration on the risk of colorectal
cancer in peri- and postmenopausal women.
MATERIALS AND METHODS
Study design
A subset of data from a large population-based nested case–
control study were analysed to investigate the effects of oral and
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lTDE on the risk of colorectal cancer risk among peri- and
postmenopausal women in Saskatchewan, a province in Canada.
Saskatchewan Health (SH) is a provincial government department
that maintains electronic health service databases as part of its
publicly funded health system. These databases were used as
sources of health services information for this study. Over 99% of
the Saskatchewan population are registered with Saskatchewan
Health and about 91% are eligible for outpatient prescription drug
benefits (Downey et al, 2000). The majority of those not eligible are
registered members of First Nations who receive prescription drug
benefits under a federal program.
Study subjects
Women, 50 years of age and older, diagnosed with histologically
confirmed colorectal cancer between January 1, 1981 and June 30,
1998 were identified using records from the Saskatchewan Cancer
Agency (SCA) cancer registry, which has been in existence since
1932 and computerised since 1970 (Rawson and Robson, 2000).
Cancer cases are identified by the SCA using both pathology
reports and physician service claims, and therefore the registry is
one of the most complete in Canada.
All cases and controls eligible for this study had to have had at
least 5 years of registration with SH, had to have been eligible for
outpatient prescription drug benefits and not have been diagnosed
with cancer (except for nonmelanoma skin cancer and cancer of
the cervix in situ) prior to the index date. Saskatchewan Cancer
Agency records were used to verify that participants had not had
previous cancer diagnoses.
Using SH electronic records, four controls were matched on the
year of birth (71 year) to each identified case. Specifically, a
control had to have been living in Saskatchewan at the time the
colorectal cancer case (to whom she was matched) was diagnosed
with cancer (index date). For each case, 16 potential controls were
randomly sampled using incidence density sampling (Rothman
and Greenland, 1998), with replacement, from the pool of eligible
controls. These controls were screened for the absence of a history
of diagnosed cancer prior to a specific index date, using records of
the SCA. Women identified as having had cancer prior to their
index dates were excluded as potential controls. Controls who did
not have histories of cancer prior to their index dates were retained
and, from them, four controls per case were randomly sampled
without replacement. In this analysis, we included only women
with index dates (for each case–control set, the date of the case
cancer diagnosis) on January 1, 1992 or later.
Ascertainment of oestrogen exposure
Dispensing data were ascertained for all forms of oestrogen: oral,
transdermal patch, and vaginal creams and rings listed in the
Saskatchewan Formulary. For each woman in the study, the type of
formulation, strength, and number of oestrogen units dispensed,
prior to index dates, were obtained from the records of the
outpatient prescription drug plan database, originally established
in 1975. Prescription drug dispensing data were ascertained for
each woman from the time her prescription drug coverage began,
until the date of colorectal cancer diagnosis for cases or assigned
index dates for controls.
Transdermal oestrogen replacement was listed in the Formulary
on July 1, 1988 with unrestricted coverage, and it was moved to
restricted coverage on January 1, 1997 (oestrogen exposure after
June 30, 1996 is not relevant for the current analysis, see
Definitions of oestrogen exposure). There was also a break in
complete data capture for all dispensed prescriptions between July
1, 1987 and December 31, 1988. For this period of time, the HRT
exposure assigned to each woman was based on her exposure
status before and after the 18-month period. No exposure was
assigned if she did not have a prescription dispensed during the
year before or after the break, one additional year of transdermal
or OE exposure was assigned if she had had at least one
transdermal or OE prescription dispensed during the year prior
to, or, during the year following the break.
Definitions of oestrogen exposure
Women were classified according to history of HRT use: TDE use
only; OE use only; or use of TDE or OE without exclusion of
women who may have used both OE and TDE. Exposure to HRT
during the 2 years prior to index dates was not included in
exposure calculations, because of evidence suggesting that women
who begin to feel unwell as a result of undiagnosed cancer may
discontinue HRT, leaving primarily healthy women as HRT users
(Sturgeon et al, 1995). In addition, exposure in the more distant
past is likely to be more relevant for cancer incidence. A woman
was identified as an ‘ever’ user if she had received at least one
prescription of TDE or OE prior to her index date, excluding the 2
years immediately preceding it. This reference point will hereafter
be referred to as the reference date. Women who had used HRT
only during the 2 years prior to their index date and women who
had received prescriptions for oestrogen containing vaginal creams
or rings only, were included in the reference groups. Vaginal
oestrogen use has been associated with poor compliance, and has
been documented to have varying degrees of absorption with
primarily local rather than systemic effects (Santen et al, 2002).
A woman was classified as having been exposed during any
given year if she had been dispensed at least one prescription of
OE or TDE oestrogen in that year. The cumulative number of years
of exposure was determined and duration of use was classified
according to short-term (o3 years) or long-term use (X3 years).
A 3-year threshold was selected, a priori, since it was felt that too
few women would have had the opportunity to have been exposed
to TDE for a longer period of time.
Ascertainment of covariates
The use of oral contraceptives, cardiovascular system (CVS) drugs,
central nervous system (CNS) drugs, and prescription nonsteroidal
anti-inflammatory drugs (NSAIDs) and vitamins, and other
hormones were also ascertained from the outpatient prescription
drug plan database for the period of time preceding index dates.
The history of having had a sigmoidoscopy and the frequency of
physician visits during the 5-year period prior to index dates were
ascertained for all cases and controls, using records of the medical
services database.
Statistical analysis
Conditional logistic regression was used to calculate the odds
ratios (ORs) and 95% confidence intervals (CIs). The effect of age
was controlled for with matching and, where matching was broken,
age-adjusted ORs were obtained with the inclusion of age in the
regression model. The confounding effects of covariates, identified
a priori, were assessed using the criteria of observing a change in
ORs of 10% or more. Backward and forward model selection
methods were used to identify the best regression model.
All associations between TDE and OE and risk of colorectal
cancer were examined among all women and for the subgroup who
had not had a sigmoidoscopy 3–5 years prior to index dates. The
analysis could not be carried out among women who had had a
sigmoidoscopy during this period of time, because too few women
had had the procedure.
An unmatched analysis was also carried out where a direct
comparison was made between TDE and OE on the risk of
colorectal cancer. In this analysis, women exposed to TDE were
compared with women who had used OE exclusively (reference
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unconditional logistic regression.
A statistical test for linear trend was carried out for the duration
of HRT use by redefining short and longer duration (o3o rX3
years) of TDE and OE use as ordinal variables, and assessing their
level of significance in a logistic regression model. All statistical
analyses were carried out using SAS software (SAS Institute,
Version 8, 1999).
RESULTS
In all, 1261 cases and 4916 age-matched controls had index dates
between January 1, 1992 and mid-1998. Of these, 1197 cases had
histologically confirmed colorectal cancer. The health-related
characteristics of these 1197 colorectal cancer cases and their
4669 controls are outlined in Table 1. Cases and controls had mean
ages of 73.8 (s.d. 10.2) years. Just over 14% of women had received
at least one prescription of vaginal oestrogen creams or rings,
without having been dispensed OE or TDE. In total, 22.8 and 2.7%
of cases had been dispensed OE and TDE, respectively, compared
with 25.3 and 4.1% of controls. The use of prescription vitamin,
cardiovascular, and CNS drugs did not differ between cases and
controls, but there was a tendency for controls to use more
NSAIDs during the 15 years prior to index dates. Not surprisingly,
important differences were observed between cases and controls
for having had a sigmoidoscopy during the year immediately
preceding the index date (70.0 vs 2.3% for cases and controls,
respectively). Only minor differences were observed for having had
a sigmoidoscopy during the 2–5 and 3–5 years preceding the
index dates. During the year preceding the index date, 65.1% of the
cases also visited their physician 15 times or more, compared with
28.8% of controls. The frequency of physician visits 2–5 years
prior to index dates did not differ greatly between cases and
controls.
The number of women, among cases and controls, exposed to
various oestrogen formulations prior to the reference date, are
presented in Table 2. A total of 63.8% of cases and 63.5% of
controls had never been exposed to any oestrogen formulation.
Except in the case of vaginal oestrogen, where an equal percentage
of women had been dispensed prescriptions, slightly more controls
than cases had been dispensed at least one prescription of OE or
TDE. Some of the women had received OE and TDE exclusively,
while others had received other oestrogen formulations at some
time.
Prescription drug use only minimally altered ORs for oestrogen
and colorectal cancer (less than 10%), and therefore only age-
adjusted ORs are presented. ‘Ever’ use of OE was associated with
an OR of 0.82 (95% CI: 0.70–0.97) (Table 3). The ‘ever’ use of TDE
was associated with an OR of 0.60 (95% CI: 0.39–0.92). Among
women who had ‘ever’ used only TDE, the OR associated with
colorectal cancer was 0.32 (95% CI: 0.13–0.79). The ORs for ‘ever’
use of OE or TDE among women who had not had sigmoidosco-
pies were not markedly different from that of the entire group.
The association between colorectal cancer risk and duration of
OE use is outlined in Table 4. Odds ratios for short-term, less than
3 years of use (OR¼0.90 (95% CI: 0.73–1.01)), and longer
duration of 3 years of OE use or more (0.75 (95% CI: 0.60–0.93)),
were below one for OE users who may have also used TDE
oestrogen. This was also true for women who had used OE only
(OR¼0.89 (95% CI: 0.72–1.10) and 0.77 (95% CI: 0.61–0.96), for
short- and long-term use, respectively). The statistical tests for
linear trend for duration of use were statistically significant for
both OE and OE only (P¼0.01 and 0.02, respectively). Similar
point estimates were obtained for women who had not had a
sigmoidoscopy 3–5 years prior to index dates. The test for linear
trend remained significant for all OE use (P¼0.02), but not for OE
only use (P¼0.07).
Table 1 Health-related characteristics of cases and controls
Cases
(n¼1197) (%)
Controls
(n¼4669) (%)
Age in years at index date
(mean (SD))
73.8 (10.2) 73.8 (10.2)
Ever use of prescription drugs
prior to index date
Vaginal oestrogen cream
or ring only
14.5 14.2
Oral oestrogen 22.8 25.3
Transdermal oestrogen 2.7 4.1
Cardiovascular drugs 68.0 66.0
Central nervous system drugs 70.8 73.1
Oral contraceptives 1.4 1.4
Other hormones and substitutes 37.7 40.0
Vitamins 18.4 18.2
NSAIDs use in years before the
index date
1–5 49.1 56.5
6–10 52.2 57.4
11–15 56.0 58.7
History of sigmoidoscopy or colonoscopy
Year before the index 70.0 2.3
2–5 years before the index 9.5 8.5
3–5 years before the index 6.5 6.9
Frequency of doctor visits in year
before index date
0–2 3.1 20.1
3–7 6.5 26.2
8–14 25.3 25.0
15+ 65.1 28.8
Frequency of doctor visits 2-5 years before index date
0–9 12.9 13.8
10–24 20.5 20.3
25–59 39.0 42.2
60+ 27.5 23.7
Table 2 Use of oral (OE), transdermal (TDE), and vaginal oestrogen
creams or rings among cases and controls prior to the reference date (2
years prior to index date)
Cases (N¼1197) Controls (N¼4669)
Formulation N % N %
Never use of HRT or vaginal
creams or rings
764 63.8 2838 63.5
Vaginal creams or rings only 177 14.8 661 14.2
OE only
a 230 19.2 1013 21.7
OE (may have used TDE)
b 251 21.0 1112 23.8
TDE only
c 5 o0.1 58 1.3
TDE (may have used oral)
d 26 2.2 157 3.4
aIn total, 62 (27%) of these cases and 340 (34%) of these controls had also been
dispensed at least one prescription of vaginal cream or ring prior to the reference
date.
bA total of 66 (26%) of these cases and 376 (34%) of these controls had also
been dispensed at least one prescription of vaginal cream or ring prior to the
reference date.
cOne (20%) of these cases and 16 (28%) of these controls had also
been dispensed a prescription of vaginal cream or ring prior to the reference date.
dFive (19%) of these cases and 52 (33%) of these controls had also been dispensed a
prescription of vaginal cream or ring prior to the reference date.
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past, the ORs were 0.69 (95% CI: 0.43–1.10) for less than 3 years of
TDE use, and 0.33 (95% CI: 0.12–0.95) for 3 or more years of TDE
use (Table 5). The linear test for trend was statistically significant
(P for trend¼0.01). Similar results were observed for TDE use
among women who had not had a sigmoidoscopy 3–5 years prior
to index dates, with the test for linear trend remaining significant
(P¼0.01). For TDE users only, the same trend in decreasing ORs
was observed with increasing duration of use; however, only five
cases had been exposed to TDE only and only one case was
exposed for 3 or more years.
An analysis was carried out to determine the association
between TDE use and colorectal cancer risk among HRT users
(cases N¼235; controls N¼1071) (Table 6). The reference
category in this analysis comprised women who had used OE
exclusively. Relative to these, women who had used TDE only had
an OR of 0.37 (95% CI: 0.15–0.94) and, similarly, among the
women who had not had a sigmoidoscopy 3–5 years prior to the
index dates, the OR was 0.32 (95% CI: 0.12–0.90).
DISCUSSION
The majority of observational studies (Furner et al, 1989; Jacobs
et al, 1994; Folsom et al, 1995; Newcomb and Storer, 1995; Persson
et al, 1996; Kampman et al, 1997; Fernandez et al, 1998; Grodstein
et al, 1998, 1999; Nanda et al, 1999; Prihartono et al, 2000) and the
results from the WHI (Writing Group for the Women’s Health
Initiative Investigators, 2002) randomised controlled trial suggest
that oral conjugated oestrogens reduce the risk of colorectal cancer
by 20–30%. The effect on colorectal cancer risk of oestrogen
replacement delivered by the transdermal mode has not been
Table 3 Age-adjusted odds ratios and 95% confidence intervals for incidence of colorectal cancer with ever use of oral and transdermal oestrogen
All women Among women who had not had a sigmoidoscopy
a
Cases (N¼1197) Controls (N¼4669) OR
b 95% CI Cases (N¼1115) Controls (N¼4366) OR
b 95% CI
Unexposed
c 941 3499 1.00 880 3297 1.00
Oral
d 251 1112 0.82 0.70–0.97 231 1015 0.85 0.72–1.01
Transdermal
d 26 157 0.60 0.39–0.92 23 144 0.58 0.37–0.92
Transdermal only 5 58 0.32 0.13–0.79 4 54 0.27 0.10–0.76
aSigmoidoscopy 3–5 years prior to the index date.
bCases and controls matched on age.
cIncludes women who may have used vaginal oestrogen creams or rings only and
women who had received an HRT prescription during the 2-year period prior to the index date.
dMay have used other HRTs.
Table 4 Age-adjusted odds ratios and 95% confidence intervals for incidence of colorectal cancer and duration of oral oestrogen use
All women Among women who had not had a sigmoidoscopy
a
Cases (N¼1197) Controls (N¼4669) OR
b 95% CI P for trend Cases (N¼1115) Controls (N¼4366) OR
b 95% CI
Oral oestrogen
c
Unexposed
d 941 3499 1.00 880 3297 1.00
o3 years 135 548 0.90 0.73–1.01 126 504 0.93 0.75–1.16
X3 years 116 564 0.75 0.60–0.93 0.01 105 511 0.77 0.61–0.97
Oral oestrogen only
Unexposed
d 941 3499 1.00 880 3297 1.00
o3 years 124 511 0.89 0.72–1.10 116 472 0.92 0.74–1.15
X3 years 106 502 0.77 0.61–0.96 0.02 96 453 0.79 0.62–1.01
aSigmoidoscopy 3–5 years prior to the index date.
bCases and controls matched on age.
cMay have used transdermal oestrogen.
dIncludes women who may have used vaginal
oestrogen creams or rings only and women who had received an HRT prescription during the 2-year period prior to the index date.
Table 5 Age-adjusted odds ratios and 95% confidence intervals for incidence of colorectal cancer and duration of transdermal oestrogen use
All women Among women who had not had a sigmoidoscopy
a
Cases (N¼1197) Controls (N¼4669) OR
b 95% CI P for trend Cases (N¼1115) Controls (N¼4366) OR
b 95% CI
Transdermal oestrogen
c
Unexposed
d 941 3499 1.00 880 3297 1.00
o3 years 22 115 0.69 0.43–1.10 20 106 0.68 0.42–1.11
X3 years 4 42 0.33 0.12–0.95 0.01 3 38 0.29 0.09–0.94
aSigmoidoscopy 3–5 years prior to the index date.
bCases and controls matched on age.
cMay have used oral oestrogen.
dIncludes women who may have used vaginal oestrogen
creams or rings only and women who had received an HRT prescription during the 2-year period prior to the index date.
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cancer that is as great, and possibly greater, in magnitude than that
reported for OE replacement therapy.
Although our results for transdermal and OE were not adjusted
for known important risk factors for colorectal cancer including
diet and physical activity, we were able to investigate the impact of
some potential covariates obtained from prospectively recorded
healthcare databases. The impact of the past use of prescription
NSAIDs and vitamins, the use of oral contraceptives, and the
frequency of physician visits prior to index dates had a negligible
effect on ORs. The minimal impact of covariates including diet and
physical activity on the measures of association between HRT and
colorectal cancer has been reported by other investigators
(Kampman et al, 1997; Fernandez et al, 1998; Grodstein et al,
1998; Prihartono et al, 2000).
We also report results among women who had not had a
sigmoidoscopy during the 3–5-year period prior to index dates.
All ORs remained strongly protective for TDE and some
associations became even more protective. We assumed that a
sigmoidoscopy during this time period was a ‘screening’
sigmoidoscopy rather than a ‘diagnostic’ procedure. The impact
of having had a sigmoidoscopy during this time could conceivably
have a protective effect, if premalignant polyps had been removed
(Winawer et al, 1993). We did not, however, have information on
whether or not a polypectomy was performed, nor did we have
information to indicate the reason for which a woman had had a
sigmoidoscopy.
The protective effect of having had a polypectomy during a
sigmoidoscopy could falsely be attributed to HRT if a woman who
had used HRT had been more likely to have had this procedure
performed. The association between HRT and colorectal cancer
was not examined among women who had had a sigmoidoscopy
3–5 years prior to index dates, because too few women had had
the procedure. However, in the majority of women who had not
had a sigmoidoscopy at that time, the results for HRT remained
protective. We can therefore rule out the impact of having had a
polypectomy playing a role in the observed protective effect.
Women choosing to use HRT are known to be different from
women choosing not to use HRT, and it had been suggested prior
to the release of WHI results that some of these differences may be
responsible for many of the protective effects against chronic
diseases attributed to HRT (Barrett-Connor, 1991; Matthews et al,
1996; Brett and Madans, 1997). However, in many studies, even in
well-designed studies where all known important covariates are
measured prospectively (Grodstein et al, 1998), crude relative risks
have not been very different from multivariate relative risks. It is of
relevance to our results that many of the healthy lifestyle
characteristics associated with HRT use are also likely to be
associated with TDE use. Whether health-related differences exist
between transdermal and OE users has not to our knowledge been
explored. We examined the use of prescribed vitamins, NSAIDs,
having had a sigmoidoscopy 3–5 years prior to the index date and
frequency of physician visits among women who had been
prescribed OE and TDE. The histories were very similar in these
two groups. Transdermal oestrogen users were somewhat younger
(mean 63.8 (s.d. 8.6) years) than OE users (mean 68.6 (s.d. 9.0)
years), but all analyses were age-adjusted either by matching
(conditional logistic regression) or in analyses where the matching
was broken, by including age as a covariate in the model. There is
no evidence to suggest that differences, if they exist, would be as
extreme as the differences between HRT users and nonusers. In the
analysis where women who had used OE comprised the reference
group, we eliminated the important potential for bias that may
exist with a comparison group of non-HRT users. The protective
effect of TDE remained.
Our study is limited by the fact that we only have a small
number of women with colorectal cancer who are exposed only to
TDE. We do, however, have a sufficient number of exposed
controls and, if TDE is truly protective, we may always have fewer
exposed cases than controls. Despite a small number of exposed
cases, some of our findings were significant. Nonetheless, in order
to study the effect of the duration of TDE use adequately, a larger
population with a longer history of TDE use must be studied.
An important strength of this study is the fact that we have
highly accurate oestrogen exposure and diagnostic data, prospec-
tively documented for all of our subjects. This avoids the potential
problem of violations of temporal order, misclassification of
exposure data, and selection bias due to incomplete diagnostic
information, which can plague case–control studies. We also have
accurate data from health service databases for all of our subjects,
with regard to the dispensing of several other prescription drugs,
and history of having had a sigmoidoscopy. Since 91% of the
Saskatchewan population is eligible to receive provincial prescrip-
tion drug benefits, our results are generalisable to the general
population, with the exception of members registered with First
Nations, who receive benefits under a federal program. It must
therefore be cautioned that our results are not generalisable to this
group.
Clinical studies have revealed metabolic differences between
transdermal and OE. The induction of hepatic protein synthesis
that occurs with OE administration (sex hormone-binding
globulin, corticosteroid-binding globulin, thyroxine-binding glo-
bulin, transferrin, ceruloplasmin, apolipoprotein A1, rennin
substrate, and various coagulation and fibrinolysis factors) is
avoided with TDE (Chetkowski et al, 1986; Crook, 1997). The
estradiol/estrone ratio produced with TDE administration is closer
to premenopausal levels, than is the ratio produced with OE
administration (Chetkowski et al, 1986; Jewelewicz, 1997; IARC
Working Group on Hormonal Contraception and Post-menopau-
sal Hormonal Therapy, 1999). In addition, with the TDE patch, the
release of oestrogen is constant and the peaks and troughs
characteristic of OE are avoided (Jewelewicz, 1997). The clinical
relevance of these different biological properties is an area that
requires study.
In summary, the reduction in colorectal cancer risk with TDE
use has not previously been reported and warrants further
investigation. Knowing more about the differences in health
outcomes between TDE and OE could help women and their
Table 6 Age-adjusted odds ratios and 95% confidence intervals for incidence of colorectal cancer associated with duration of transdermal oestrogen use
among postmenopausal oestrogen users (oral oestrogen users are the reference group)
All women Among women who had not had a sigmoidoscopy
a
Cases
(N¼235)
Controls
(N¼1071)
Age-adjusted
OR 95% CI
Cases
(N¼216)
Controls
(N¼979)
Age-adjusted
OR 95% CI
OE use only 230 1013 1.00 212 925 1.00
TDE use only 5 58 0.37 0.15–0.94 4 54 0.32 0.12–0.90
aSigmoidoscopy 3–5 years prior to the index date.
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and maximise the benefits of treating distressing menopausal
symptoms.
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